About Berry Genomics
Berry Genomics is a company based in Beijing (China) founded in 2010. Berry Genomics has raised $16 million across 3 funding rounds from investors including Qiming Venture Partners and Legend Capital. The company has 1,400 employees as of December 31, 2024. Berry Genomics operates in a competitive market with competitors including Natera, SYNLAB, Rejuvenate Bio, Novogene Corporation and Progenity, among others.
- Headquarter Beijing, China
- Employees 1400 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Berry Genomics Co. Ltd. Class A
-
Annual Revenue
$146.59 M (USD)-6.64as on Dec 31, 2024
-
Net Profit
-$26.36 M (USD)54.96as on Dec 31, 2024
-
EBITDA
-$2.93 M (USD)71.96as on Dec 31, 2024
-
Total Equity Funding
$16 M (USD)
in 3 rounds
-
Latest Funding Round
$16 M (USD), Series B
Apr 02, 2015
-
Investors
Qiming Venture Partners
& 1 more
-
Employee Count
1400
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Berry Genomics
Berry Genomics is a publicly listed company on the SZSE with ticker symbol 000710 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Berry Genomics
Berry Genomics has successfully raised a total of $16M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $16 million completed in April 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Berry Genomics
Berry Genomics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Qiming Venture Partners and Legend Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are directed toward multiple sectors.
|
Locked | Locked | Locked | |
|
Venture Capital firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Berry Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Berry Genomics
Investment portfolio details for Berry Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Berry Genomics
Detailed financials for Berry Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Berry Genomics Comparisons
Peer comparison for Berry Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Berry Genomics
Berry Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Natera, SYNLAB, Rejuvenate Bio, Novogene Corporation and Progenity, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of medical diagnosis and clinical laboratory analysis services
|
|
| Locked | Locked | Locked |
Gene-editing platform and anti-aging therapy for dogs are developed.
|
|
| Locked | Locked | Locked |
Genomic services and solutions with NGS expertise are provided.
|
|
| Locked | Locked | Locked |
Non-invasive prenatal genomic testing is provided for genetic disorders.
|
|
| Locked | Locked | Locked |
Meta-genomics platforms and services for microbiome studies are provided.
|
Detailed competitors of Berry Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Berry Genomics
Complete news archive for Berry Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Berry Genomics
Berry Genomics was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Berry Genomics is headquartered in Beijing, China.
Berry Genomics is a funded company, having raised a total of $16M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Berry Genomics is 1,400.
Annual revenue of Berry Genomics is $146.59M as on Dec 31, 2024.
Biotech company that develops and commercializes next-generation sequencing based integrated solutions for clinical applications. Focuses majorly on genetic testing and oncology testing. It is one of the leading providers of non-invasive prenatal testing (NIPT) in China. Its products include NextSeq CN500 gene sequencing platform and supply of consumables to the sequencing system. In Dec 2016, the company went public on Chinas Shenzhen market via a reverse merger with Chengdu Tianxing Instrument Meter, a shell auto company, in a deal that values Berry Genomics at 618.8M.
Berry Genomics's top competitors include Natera, Novogene Corporation and BGI.
Yes, Berry Genomics is publicly traded on SZSE under the ticker symbol 000710.
Berry Genomics has 2 investors. Key investors include Qiming Venture Partners, and Legend Capital.
The ticker symbol of Berry Genomics is 000710 on SZSE.